127 related articles for article (PubMed ID: 38678671)
1. Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
Li Y; Sun H; Bai C; Hu Y; Tang J; Zhang Y; Chen J; Zhong Z; He Y; Hu K; Yang J
Int Immunopharmacol; 2024 May; 133():112157. PubMed ID: 38678671
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
[TBL] [Abstract][Full Text] [Related]
3. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
4. Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer.
Liu X; Pu W; He H; Fan X; Zheng Y; Zhou JK; Ma R; He J; Zheng Y; Wu K; Zhao Y; Yang SY; Wang C; Wei YQ; Wei XW; Peng Y
Cancer Lett; 2019 Aug; 458():76-85. PubMed ID: 31125641
[TBL] [Abstract][Full Text] [Related]
5. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
6. Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
Li Y; Xiao X; Wang H; Zhou Q; Jin Z; Zhang Y; Wang Y; Yue F; Zhou S; Yang J
Eur J Pharmacol; 2021 Oct; 909():174411. PubMed ID: 34390710
[TBL] [Abstract][Full Text] [Related]
7. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
Shen R; Li J; Ye D; Wang Q; Fei J
Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):894-901. PubMed ID: 27590062
[TBL] [Abstract][Full Text] [Related]
8. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
9. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity
Son DJ; Zheng J; Jung YY; Hwang CJ; Lee HP; Woo JR; Baek SY; Ham YW; Kang MW; Shong M; Kweon GR; Song MJ; Jung JK; Han SB; Kim BY; Yoon DY; Choi BY; Hong JT
Theranostics; 2017; 7(18):4632-4642. PubMed ID: 29158850
[No Abstract] [Full Text] [Related]
10. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
Lewis KM; Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Fridley C; Siller R; Tweardy DJ
Lung Cancer; 2015 Nov; 90(2):182-90. PubMed ID: 26410177
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
13. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
14. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
Ida L; Yamaguchi T; Yanagisawa K; Kajino T; Shimada Y; Suzuki M; Takahashi T
Cancer Sci; 2016 Feb; 107(2):155-61. PubMed ID: 26661061
[TBL] [Abstract][Full Text] [Related]
17. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.
Tong Y; Liu Y; Zheng H; Zheng L; Liu W; Wu J; Ou R; Zhang G; Li F; Hu M; Liu Z; Lu L
Oncotarget; 2016 May; 7(21):31413-28. PubMed ID: 27119499
[TBL] [Abstract][Full Text] [Related]
18. HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism.
Lu L; Li H; Wu X; Rao J; Zhou J; Fan S; Shen Q
Cell Prolif; 2020 Mar; 53(3):e12777. PubMed ID: 32022328
[TBL] [Abstract][Full Text] [Related]
19. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
20. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
